We developed and compared five scoring systems designed to quantitate therapeutic response in cases of oropharyngeal candidiasis. We utilized prospectively collected data on 114 patients treated with several doses of the azole D0870. Patients were infected with fluconazole-susceptible (n Å 49) or -resistant organisms (MIC, §16 mg/mL; n Å 61). Patients with fluconazole resistance had lower CD4
Episodes of oropharyngeal candidiasis (OPC) are almost unieral problems have hampered the interpretation of clinical triversal occurrences for patients with AIDS [1, 2] . Esophageal als. First, there are often diverse oral symptoms, some of which candidiasis is the AIDS-defining event in 13% of patients, may not be attributable to OPC. For example, there is overlap and 22% develop it during the course of AIDS [3] . OPC and with other HIV-associated conditions such as gingivitis and esophageal candidiasis tend to be chronic, relapsing, and inside effects of antiretroviral drugs (such as dry mouth with use creasingly symptomatic, with progressive immune paresis.
of didanosine), so the lack of a symptomatic response may not OPC in HIV-infected patients usually responds to oral imidazbe a reliable indicator of persistence of OPC. ole therapy [4] . However, at later stages of disease, episodes Similarly, signs may be diverse. Pseudomembranous candibecome more frequent and often refractory to treatment with diasis is the classic form, but OPC may also present as an these agents [1] . The widespread use of fluconazole, itraconaatrophic form with ulcers, as well as angular cheilitis, with zole, and ketoconazole has led to the emergence of resistant localized disease at the corners of the mouth, and as an eryisolates of Candida albicans [5, 6] , especially in the context thematous form with localized discomfort and erythema [10] . of HIV infection [1, 7 -9] . The ongoing development of new Assessment of response in patients with extensive oral hairy agents is necessary to increase the therapeutic options; the main leukoplakia may be imprecise. Individual clinicians are likely therapy currently available is with intravenous amphotericin to be inconsistent in their assessment of extent of disease. B, which has attendant problems of toxic effects, particularly
In addition, the symptoms of esophageal candidiasis may be renal impairment.
mimicked by a number of other pathologies, such as cytomegaPreviously, the clinical assessment of OPC in therapeutic lovirus or herpes simplex virus esophageal infection, in the trials has received little attention. In AIDS patients with the presence or absence of OPC. This can make accurate diagnosis pseudomembranous forms of OPC, disappearance of visible and assessment of therapeutic response with regard to esophalesions, with some diminishment of symptoms, has been taken geal symptoms particularly problematic, unless patients unas sufficient evidence of a therapeutic response. However, sevdergo endoscopic examination [11] .
In patients with early AIDS or AIDS-related complex, response to treatment can usually be simply evaluated by inspection of the oral mucosa for the presence or absence of the susceptible organisms. Although clearly not a full response or an exclusion criterion. Female patients who were pregnant, breast-feeding, or using unreliable contraception were also excure with therapy, symptomatic improvement is of benefit to patients. However, in order to compare one therapy with ancluded. other, some objectivity is required in the assessment of response, especially in the evaluation of novel antifungal agents.
Description of Studies
From the clinician's standpoint, it would be helpful to understand more about the utility of certain symptomatic responses Study 003. Study 003 [16] was a two-phase single-dose study with an open phase (12 subjects) followed by a doublein predicting a mycologic resolution and, conversely, whether certain symptoms and clinical findings at the start of therapy blind, parallel randomized phase with two doses (12 subjects in each group). Treatment was given for 5 days. Patients were could reliably predict the presence of a resistant strain, with a correspondingly high MIC value for the isolate.
excluded from the study if they had previously received fluconazole therapy that failed. Clinical assessments were made at D0870 is a bis-triazole agent with good in vitro activity against C. albicans and other Candida species [13] [14] [15] . Early clinical enrollment, on day 3, at the end of therapy, and on days 7 and 14 after the end of therapy. trial results are encouraging [16, 17] . We had the opportunity to examine the therapeutic response data from all these trials of Study 012. For study 012 [17] , patients who had OPC that had failed to respond to fluconazole therapy at dosages of §100 D0870 for OPC to find the optimal means of assessing response in those with fluconazole-susceptible and -resistant OPC.
mg/d for at least 7 days were recruited. This was an open, nonrandomized trial assessing a single dose of D0870 in 27 The aims of the present study were (1) to compare symptoms, signs, and results of quantitative Candida cultures for patients subjects. Treatment was given for 7 days. Clinical assessment was made at enrollment, on day 3, at the end of therapy, and with fluconazole-susceptible and fluconazole-resistant OPC; (2) to compare assessments of therapeutic response of OPC on days 7 and 14 after the end of therapy. Study 018. Enrollment criteria for study 018 were the same caused by azole-susceptible and fluconazole-resistant Candida, in order to define the optimal criteria for assessing therapeutic as for study 012. The trial was a dose-escalation study in which 48 patients were recruited. Patients in the first cohort were response; and (3) to validate, if possible, a clinical scoring system that accurately reflects therapeutic response.
treated with a given dose of D0870 (dose A), and if the response rate was £80% and safety had been established, the next cohort To do this, we investigated whether patients infected with azole-susceptible and -resistant strains of Candida differ in was treated with a higher dose. The same criteria were used to elevate the dose further, for a total of five dosing steps. their clinical presentation and determined the correlation (if any) of therapeutic outcome of individual symptoms with Forty-eight patients were recruited at four doses. Subjects were assessed for clinical response on days 4, 7, and 10 (end of global outcome. We also examined the effect of treatment on cfu measurements of isolates from these patients. We sought therapy) and following therapy. to derive a simple means of assessing the efficacy of antifungal agents in OPC caused by fluconazole-resistant Candida. We
Clinical Assessment of Efficacy
propose a standard means of objective assessment of outcome of therapy for OPC caused by azole-resistant Candida in HIVComparable clinical data concerning symptoms and clinical signs of OPC, in addition to the response of each to treatment, infected patients.
In this article, the term fluconazole-refractory OPC is synonwere collected in all the studies. Each symptom was graded as mild (causing minimum discomfort and not interfering with ymous with therapeutic failure of fluconazole, and the term fluconazole-resistant OPC means OPC that failed to respond everyday activities), moderate (interfering with everyday activities), or severe (e.g., incapacitating). For study 018, data on to fluconazole and is caused by a fluconazole-resistant strain of Candida.
the symptom ''burning of mouth'' were not recorded; hence, the highest grading of ''burning of mouth'' and ''oral pain'' in studies 003 and 012 was taken as equivalent to that of ''oral Methods pain'' for study 018. An oral-cavity examination was performed and estimated We analyzed data gathered for three studies (numbered 003 [16] , 012 [17] , and 018 [unpublished]) of D0870 in HIVcoverage over the soft palate, left and right buccal areas, and tongue areas was scored as nil, scant, moderate, or confluent. positive individuals with pseudomembranous OPC. All three were prospective multicenter studies conducted before the inFor study 018, coverage was graded slightly differently, as absent, õ25%, 25% -50%, 51% -75%, 76% -99%, or 100%. troduction of protease inhibitors and mostly during the era of monotherapy for HIV infection. Adults with normal electrocarFor the purposes of comparison between studies, 25% -75% coverage was deemed equivalent to ''patchy'' in the previous diographic and liver function test findings who had no history of heart or liver disease were enrolled. Comedication with studies, and 76% -100% was considered equivalent to ''severe'' or ''confluent.'' In addition, for study 018, the overall warfarin, cyclosporine, sulfonylureas, nortriptyline, antiarrhythmics, terfenadine, astemizole, or systemic antifungals was coverage of the mucosa was estimated.
/ 9c63$$mr08 02-22-99 13:35:55 cida UC: CID At the end of therapy, the individual outcome for each sign at 35ЊC for 24 hours. Endpoints were determined spectrophotometrically, with the first well showing §50% inhibition being and symptom was defined as cleared (complete resolution of signs and symptoms), improvement (partial clearance of signs defined as the MIC. C. albicans ATCC 10231 (MICs: D0870, 0.03 mg/mL; fluconazole, 0.5 -2 mg/mL) served as a control and symptoms), failure (no diminishment of signs or symptoms), relapse, or unevaluable/misdiagnosis. Global outcome strain. Resistance was defined as an MIC of §16 mg/mL for fluconazole. was defined as resolved (determined by clinical resolution of lesions and symptoms), improvement (determined by reduction in the severity and/or number of symptoms and lesions but Patients with fluconazole-susceptible isolates were compared were deemed unevaluable if their conditions were judged to be with those with resistant isolates at study enrollment with remisdiagnosed, if there were major violations of entry criteria, if spect to CD4 / cell count, total number of symptoms and freany concomitant antifungal agent had been used, or if pretherquency of individual symptoms, degree of coverage, and cfu apy cultures were negative. measurement at start of treatment. In the comparison of coverage, patients in studies 003 and 012 had coverage expressed
Quantitative Culture Procedure as absent, patchy, or confluent in four areas (tongue, soft palate, and left and right buccal mucosae). To enable a comparison Specimens were collected by oral swabs from each of the with study 018 patients (with global coverage estimated as a four areas of the oral cavity. Oral ''swish'' samples were also percentage: 0%, 1% -25%, 26% -50%, 51% -75%, 76% -99%, collected. Patients were instructed in the method before being and 100%), absent was scored as 0, patchy as 1, and confluent asked to rinse and gargle 10 mL of sterile distilled water for as 2; then the scores for each area were added, for a total score at least 20 seconds, before spitting the liquid into a sterile of 0 -8. Zero corresponded with 0%, 1 and 2 with 1% -25%, container. These specimens were stored at 4ЊC until dispatch 3 and 4 with 25% -50%, 5 and 6 with 51% -75%, and 7 and to the microbiology laboratory within 48 hours (usually imme-8 with 76% -100%. The comparisons were performed with a diately).
Mann-Whitney U test and Wilcoxon rank sum W test. Each oral swab was immersed in 5 mL of sterile PBS in a sterile tube that was agitated for 15 seconds, and then serial decimal dilutions in sterile PBS were made; 100-mL aliquots
Comparison of Individual Symptom Response with Global
of the dilutions were subcultured onto Sabouraud dextrose agar.
Outcome
PBS was added to each ''swish'' sample to make dilutions Our aims were to measure the predictive power of particular of 1:10, 1:50, 1:100, 1:200, and 1:400. Each dilution was agiclinical findings in relation to overall clinical outcome; to extated for 15 seconds, and a 0.1-mL sample from each dilution amine the relationship, if any, between change in cfu measurewas subcultured onto Sabouraud dextrose agar. In both cases ments (pretherapy vs. post-therapy) and clinical response; and the culture plate was then incubated at 37ЊC for 48 hours, and to determine the strength of association (assessed with use of the following day the plate was inspected for colonies typical Kendall's tau-B correlation coefficient) in each case. For the of Candida species. The number of cfu per milliliter was quanfirst goal, tables of individual symptom outcome against global tified as no growth; õ10 colonies; 10 -100 colonies; ú100 outcome were produced, and the data were compared with use colonies but not countable; or confluent growth. of Kendall's tau-B test in each case. For the assessment of cfu measurements, the median cfu values for before and after therIn Vitro Susceptibility Testing apy were calculated, and the Wilcoxon signed-rank test and Spearman's rank correlation test were performed. MIC testing of isolates against fluconazole and D0870 was performed as follows [13, 18] . RPMI-1640 broth buffered with MOPS (3-[N-morpholino]propanesulfonic acid) at a pH of 7.0
Testing of Scoring Systems
was the test medium. Five colonies of 1 mm each were picked off the culture plate, resuspended together in 5 mL of sterile Scoring system A was used initially. This weighted each clinical symptom on a scale of 0 -3, with absent scored as 0; physiological saline, and centrifuged, and the turbidity was adjusted to a 0.5 McFarland standard with sterile physiological mild, 1; moderate, 2; and severe, 3. Dysphagia was scored double, 0 -6, to weight esophageal involvement adequately, as saline. The resulting 1 1 10 6 -cfu/mL suspension was then diluted 1:50 in RPMI broth to give the final inoculum of 2 1 no endoscopy was performed. Each clinical sign was also scored from 0 to 3 (no lesions, score of 0; few spots, 1; multiple 10 4 cfu/mL. D0870 was dissolved in dimethyl sulfoxide and fluconazole in water, and each was diluted to give a final dilupatches, 2; and confluent disease, 3). The total score was derived by subtracting the post-therapy score from the pretherapy tion series of 32 -0.03 mg/mL in 100-mL microtiter wells after addition of 100 mL of yeast inoculum. Plates were incubated score. Scoring systems B, C, D, and E were later developed / 9c63$$mr08 02-22-99 13:35:55 cida UC: CID B -E, a score was given for the degree of change in each sign or symptom. These individual scores were then added together CD4 / cell count. There was a significant difference in CD4
/ cell counts between the fluconazole-resistant and -susto give an overall score. ceptible groups (Mann-Whitney, P õ .0001). The median zole-resistant strains. Burning of the mouth is a less frequent symptom in disease due to fluconazole-susceptible strains than CD4
/ cell count at baseline for patients with resistant isolates (n Å 61) was 6 (quartiles: 2, 22.5) 1 10 6 /L, and for those with in that due to fluconazole-resistant strains. Oral pain was the second most frequent symptom in disease due to fluconazolesusceptible isolates (n Å 49), 19 (quartiles: 10, 74) 1 10 6 /L. Coverage. Percentage of oral coverage was significantly susceptible or fluconazole-resistant isolates. A Kendall correlation coefficient was generated to compare any change in sympgreater at baseline in the fluconazole-resistant group than in the fluconazole-susceptible group (Mann-Whitney, P Å .0003).
tom with global outcome to determine the correlation between symptom outcome (worse, unchanged, improved, resolved) and Colony-forming units. There was no difference in cfu measurements at baseline between patients with OPC due to flucoglobal outcome. This was done for all patients and then for the two subgroups with OPC due to fluconazole-susceptible nazole-resistant Candida isolates and those with OPC due to fluconazole-susceptible strains (P Å .64).
and -resistant organisms. The results are shown in table 4. Improvement (diminishment) in certain symptoms (dysphagia and oral pain) correlates most closely with overall clinical
The presence or absence of the ''burning of mouth'' sympNumber and frequency of symptoms. There was a significant difference in both the number of symptoms and the fretom correlates well with that of oral pain. There was poor agreement between change in ''furry'' taste and change in quency of individual symptoms between the fluconazoleresistant and -susceptible groups. The median numbers of tongue lesions (agreement, 38%; kappa Å 0.14), and ''furry'' taste did not correlate with the clinical sign of tongue coating. symptoms at baseline for patients completing the study who had fluconazole-resistant disease (n Å 54) and fluconazoleDysgeusia was the most frequent symptom in the study, irrespective of the presence of OPC, and had a relatively poor susceptible disease (n Å 45) were 3 and 1, respectively (P Å .0006). Among initial symptoms, the frequency of dyscorrelation with outcome. Xerostomia (dry mouth) was also a frequent symptom but again correlated poorly with outcome. geusia (P Å .0038), dysphagia (P Å .006), and throat pain (P Å .0034) but not of retrosternal pain or oral pain was significantly White plaques (as reported by the patient) showed a close correlation with objective (i.e., physician-described) measures greater in patients with resistant disease (table 3) .
Symptom frequencies are shown in table 3. The data are of outcome. consistent with certain symptoms of OPC being more common than others, and some symptoms are more common in flucona-
Measurements of Colony-Forming Units
zole-resistant OPC than in fluconazole-susceptible OPC. Dysphagia is an infrequent symptom in disease due to fluconazoleThe change in median number of cfus of all fungal isolates between the start and end of therapy was compared by means susceptible Candida but is frequent in disease due to flucona- of the Wilcoxon matched-pairs signed-ranks test. The values than no change in the symptom but was otherwise the same as scoring system C. Scoring system E (correlation, 0.82) was the for fluconazole-susceptible vs. -resistant disease were compared with Spearman's rank correlation test.
same as scoring system D, except resolution of a symptom was weighted (/3) higher than absence of a symptom (/2). Among cases of fluconazole-susceptible OPC (n Å 40), the median starting cfu score was 4 (quartiles, 3 and 4), equivalent
Figures 4 -8 show the degree of correlation between changes in scores for symptoms and changes in scores for degree of to a value of ú100 cfu/mL. There was a nonsignificant reduction in cfu score at end of treatment, to 3 (10 -100 cfu/mL; coverage by oral patches (signs) following treatment. For each scoring system, in a considerable proportion of patients, a tenquartiles, 3 and 4). There was no correlation with clinical outcome (r s Å 0.26; P Å .11).
dency emerged for comparatively greater improvement in symptoms than reduction in oral coverage following treatment. Among cases of fluconazole-resistant OPC (n Å 52), the median cfu value was 4 (quartiles, 3 and 4) at both baseline and This was most marked for system B and C scores. Our analysis suggests dysphagia, oral pain, and oral burning are the most end of therapy. Again, there was no correlation with clinical outcome (r s Å 0.28; P Å .04).
useful symptoms to include in the scoring system. Xerostomia and dysgeusia are frequent symptoms, irrespective of the presence of OPC, and are best excluded from assessments of effi-
Scoring Systems
cacy. Scoring system C gives the best degree of differentiation between the groups where symptoms resolved, improved, or To assess the five clinical scoring systems against global outcome, Spearman's rank correlation test was performed for remained unchanged/worsened, with no overlap between those whose therapy failed and those whose symptoms cleared. The each scoring system. The patients were divided into two groups (fluconazole-susceptible vs. fluconazole-resistant disease) on data also demonstrate that scoring system C works equally the basis of MIC data (values of §16 mg/mL defined resistance and values õ16 mg/mL defined susceptibility). Global outcome of OPC was defined as follows. OPC was considered resolved if all oral lesions and symptoms of disease resolved, improved if there was some diminishment of oral lesions or symptoms or both, unchanged if oral lesions were unchanged, and worse if there was greater coverage with lesions at the end of therapy. Figures 2 and 3 show outcomes according to scoring systems A and C for fluconazole-resistant and -susceptible disease. Resolution was primarily determined by clearing of patches in the mouth. Equally good differentiation between outcomes can be seen for fluconazole-resistant and -susceptible disease.
Scoring system A, a simple-sum method, was initially tried but differentiated poorly between different outcomes, yielding a correlation of 00.37 (figure 2). Scoring system B weighted the absence of a symptom throughout more positively (/3) than resolution of the symptom (/2), and showed a correlation of 0.81 between score and global outcome. Scoring system C weighted resolution (/3) as a better outcome than absence of a symptom throughout (/2) (figure 3); this gave the best resort [19] . Few data exist regarding the efficacy of and optimal dosage for this latter option. produce a response, but this is often short-lived [19] . Itracona- MIC of õ16 mg/mL).
/ 9c63$$mr08 02-22-99 13:35:55 cida UC: CID involvement. It has been suggested that xerostomia correlates with clinical failure of fluconazole, because reduced saliva production would reduce the amount of fluconazole reaching the oral cavity. This was not confirmed by this study with D0870, another azole secreted in saliva, as the presence of xerostomia at baseline did not correlate with a poor outcome. The value of susceptibility testing is also emphasized by these data, as it is apparent that patients' fluconazole therapy may fail for many reasons, one of which is resistance of the infecting organism(s) (76% in this series). Access to susceptibility testing may well prove to be a valuable clinical tool with the continued emergence of azole-resistant isolates of C. albicans and other Candida species.
The data from the three studies provided a good range of outcomes; there was a good distribution of complete, partial, and no responses, necessary to develop and test a scoring system (table 1 ). An intuitive approach to formulating a scoring system would rate severity of signs and symptoms at the begin- ''severe throughout.'' Unless the baseline total score is integrated into the score, a poor correlation with other outcome measures will be attained, as in scoring system A. In compariOur further detailed analysis of the three studies of treatment of fluconazole-susceptible and fluconazole-resistant pseudoson, scoring system C is better because it reflects the severity of disease, in terms of number of symptoms, as well as any membranous OPC has revealed that there are marked differences in symptomatology, objective signs of disease, mycolchange following therapy. In terms of using scores for degree of coverage of the oral ogy, and therapeutic outcome between the two groups. Few previous studies have carefully examined these issues, and none mucosa by plaques of Candida, if the score includes ''confluent'' coverage for an area, then this must be attainable. From the data have been able to compare the two groups prospectively. Our analysis is limited by the two groups' imprecise matching by it became clear that ''confluent'' coverage was attainable in buccal CD4 cell count and stage of AIDS. The median CD4 cell counts were õ20 1 10 6 /L in both groups, however. Despite this caveat, we still believe the data are valuable. In addition, this work represents the first attempt to define a relationship between assessment of symptoms of OPC in patients with HIV infection and AIDS and clinical outcome following treatment with an azole.
We noted a large diversity of therapeutic outcome of individual symptoms and considerable overlap with other conditions. We found that the most useful symptoms to assess are dysphagia and oral pain (described as pain, burning, or discomfort). Loss of appetite and dysphagia lead to weight loss, and this may further worsen the clinical condition. Though cure may not be possible, a symptomatic response may well enable a patient to increase food intake considerably and improve his or her sense of well-being.
There was a poor correlation between objective and subjective measures of response, especially in cases of fluconazoleresistant disease. Many patients had a beneficial symptomatic implying that ''furry'' taste is not necessarily related to tongue / 9c63$$mr08 02-22-99 13:35:55 cida UC: CID 
